Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VV119
- Development stage
- Phase 2
- Lead developer
- Vigonvita Life Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VV119 is an orally bioavailable small molecule drug under development by Vigonvita Life Sciences for the treatment of schizophrenia. It is currently in Phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics, and preliminary efficacy in both healthy volunteers and patients with schizophrenia. The precise mechanism of action has not been defined or disclosed as of the latest updates. VV119 is classified as a new molecular entity and belongs to the antipsychotic class.
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)DRD (Dopamine receptors)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on VV119.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VV119.